-$0.09 EPS Expected for Trevena Inc (TRVN) This Quarter

Brokerages expect that Trevena Inc (NASDAQ:TRVN) will report earnings per share (EPS) of ($0.09) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Trevena’s earnings. Trevena posted earnings per share of ($0.13) during the same quarter last year, which would indicate a positive year over year growth rate of 30.8%. The company is expected to report its next quarterly earnings results on Thursday, August 1st.

On average, analysts expect that Trevena will report full year earnings of ($0.37) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will report earnings of ($0.23) per share. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Trevena.

Trevena (NASDAQ:TRVN) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02.

TRVN has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a report on Thursday, February 7th. HC Wainwright reissued a “hold” rating and set a $1.25 target price on shares of Trevena in a report on Thursday, March 14th. Finally, ValuEngine cut shares of Trevena from a “hold” rating to a “sell” rating in a report on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $4.69.

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc increased its stake in shares of Trevena by 29.2% during the third quarter. Vanguard Group Inc now owns 2,618,634 shares of the biopharmaceutical company’s stock valued at $5,552,000 after purchasing an additional 592,152 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Trevena by 29.2% in the 3rd quarter. Vanguard Group Inc. now owns 2,618,634 shares of the biopharmaceutical company’s stock worth $5,552,000 after buying an additional 592,152 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Trevena by 38.8% in the 1st quarter. BlackRock Inc. now owns 2,597,930 shares of the biopharmaceutical company’s stock worth $4,052,000 after buying an additional 725,717 shares during the last quarter. Renaissance Technologies LLC increased its holdings in shares of Trevena by 84.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,284,038 shares of the biopharmaceutical company’s stock worth $2,003,000 after buying an additional 587,100 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in shares of Trevena by 17.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 541,099 shares of the biopharmaceutical company’s stock worth $1,147,000 after buying an additional 80,437 shares during the last quarter. 21.54% of the stock is currently owned by hedge funds and other institutional investors.

Shares of TRVN stock opened at $1.31 on Friday. The company has a current ratio of 3.58, a quick ratio of 3.55 and a debt-to-equity ratio of 0.18. Trevena has a 1 year low of $0.38 and a 1 year high of $3.58. The firm has a market cap of $117.29 million, a price-to-earnings ratio of -3.12 and a beta of 2.55.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Story: What is a short straddle?

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.